Tempus AI is in a volatile, range-bound recovery rather than a clean uptrend: the stock is down 28.89% over the past year but up 3.78% year-to-date, and at $64.72 it sits at roughly 43% of its 52-week range of $40.77 to $96.29. That mid-range positioning reflects a market that has neither fully rejected nor re-embraced the story, and the 59.76% maximum drawdown underscores how punishing the downside has been for momentum holders. The stock is trading about 33% below its 52-week high but roughly 59% above its 52-week low, a wide band that argues for disciplined entry rather than chasing strength.

Short-term momentum has deteriorated sharply and diverges from the improving three-month trend: the stock fell 7.50% over the past month and 9.01% in the single session to $64.72 from $71.13, even as it gained 23.35% over three months and 15.84% over six months. That divergence signals a mean-reversion pullback within a recovering intermediate trend rather than a confirmed reversal, but the velocity of the drop is a warning. Relative strength tells the same story: -8.72 points versus SPY over one month and -44.42 over one year, yet +20.66 over three months, meaning the stock has recently been a strong outperformer that is now ceding ground. Volume of roughly 6.86 million shares on the down day suggests distribution rather than quiet profit-taking.

Key technical levels are well defined: support sits at the $40.77 52-week low, with intermediate support near the $61-62 area that held in early September, while resistance is anchored at the $96.29 52-week high and the $85 region where the September rally stalled. A breakout above $85-96 would signal the market is re-rating the Personalis-driven growth story, whereas a breakdown below $61 would put the $40.77 low back in play and confirm the one-month downtrend. With a beta of 3.54, the stock is roughly 3.5 times as volatile as the S&P 500, so position sizing must account for swings that can erase a third of value in weeks, as the 59.76% max drawdown demonstrates.

Revenue is growing at a solid but decelerating-looking pace: Q2 2026 revenue of $382.49 million rose 21.56% year-over-year versus $314.64 million in Q2 2025, and the sequential path from $334.21 million in Q3 2025 to $348.12 million in Q1 2026 to $382.49 million in Q2 2026 shows steady expansion. Diagnostics contributed $289.33 million of segment revenue, the dominant driver of the top line, while the remainder comes from data and services. The trajectory supports the growth thesis, but the 21.56% YoY rate is more moderate than the hyper-growth multiple the stock commands, making execution on the Personalis acquisition and data monetization critical to justifying further re-rating.

Profitability is thin and inconsistent: Q2 2026 net income was just $5.64 million on a 1.48% net margin, a sharp swing from a $125.92 million loss in Q1 2026 and a $54.17 million loss in Q4 2025, and operating income remained negative at -$75.91 million (-19.85% operating margin). Gross margin has been stable and improving, from 60.69% in Q1 2025 to 64.45% in Q2 2026, which is respectable for a diagnostics-and-data hybrid but not enough to offset $322.41 million in quarterly operating expenses, including $96.57 million of R&D. The Q2 profit appears flattered by $81.86 million of other income, so the underlying operating loss trajectory, not the headline EPS of $0.03, is the truer signal.

Balance sheet liquidity is a strength but cash generation is not: the current ratio is 3.13 and cash stood at $604.34 million at Q2 2026, yet free cash flow TTM is -$272.97 million and Q2 operating cash flow was -$7.53 million after a -$83.34 million Q1. Debt-to-equity of 2.70 and a debt ratio of 0.61 reflect the convertible-heavy capital structure, while ROE of -49.87% and ROA of -8.83% confirm capital is being consumed rather than compounded. Stock-based compensation of $54.12 million in Q2 alone is a meaningful dilution and cash-flow quality issue, meaning the company still depends on its cash pile and external financing rather than internal cash generation to fund growth.